Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness

doi:10.1016/0091-6749(91)90160-P

Journal of Allergy and Clinical Immunology

Volume 88, Issue 4, October 1991, Pages 661-674

https://doi.org/10.1016/0091-6749(91)90160-P Get rights and content

Abstract

Bronchial biopsy specimens were obtained by fiberoptic bronchoscopy from 21 atopic subjects with asthma, 10 atopic subjects without asthma, and 12 normal healthy control subjects. With immunohistochemical techniques and a panel of monoclonal antibodies, inflammatory cells were identified and counted in the bronchial mucosa. The mean number of leukocytes (CD45⁺) and T-lymphocytes (CD3⁺, CD4⁺, and CD8⁺) at two airway levels in the subjects with asthma tended to be higher than in the other groups, but this difference did not achieve statistical significance. Similarly, there were no significant differences in the numbers of mucosal-type or connective tissue-type mast cells, elastase-positive neutrophils, or Leu-M3⁺ cells in the airway mucosa of subjects with asthma compared with atopic subjects without asthma and healthy control subjects. In contrast, significantly more interleukin-2 receptor-positive (CD25⁺) cells and “activated” (EG2⁺) eosinophils (EOSs) were present in the airways of subjects with asthma at both proximal and subsegmental biopsy sites. When the relationships between numbers of T-lymphocytes, activated (CD25⁺) cells, and EOSs were analyzed, there were positive correlations between CD3 and EG2, between CD3 and CD25, and between CD25 and EG2 positive cells in the airways of subjects with asthma. Furthermore, the ratio of EG2⁺ to CD45⁺ cells correlated with the provocative concentration of methacholine that caused a 20% decrease of FEV₁ in hyperresponsive subjects. Although these associations do not prove a causal relationship, the results support the hypothesis that activated (CD25) T-lymphocytes release products which regulate recruitment of EOSs into the airway wall. In addition, our findings suggest that, in the large airways at least, asthma is not associated with hyperplasia of either mucosal-type or connective tissue-type mast cell.

References (31)

S Lam et al.
Cellular and protein changes in bronchial lavage fluid after late asthmatic reaction in patients with red cedar asthma
J Allergy Clin Immunol
(1987)
AB Tonnel et al.
Stimulation of alveolar macrophages in asthmatic patients after local provocation test
Lancet
(1983)
CJ Corrigan et al.
T-lymphocyte activation in acute severe asthma
Lancet
(1988)
LA Laitinen et al.
Damage of the airway epithelium and bronchial reactivity in patients with asthma
Am Rev Respir Dis
(1985)
PK Jeffery et al.
Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity
Am Rev Respir Dis
(1989)
R Beasley et al.
Cellular events in the bronchi in mild asthma and after bronchial provocation
Am Rev Respir Dis
(1989)
M Azzawi et al.
Identification of activated T-lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma
Am Rev Respir Dis
(1990)
JGR de Monchy et al.
Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions
Am Rev Respir Dis
(1985)
SE Wenzel et al.
Activation of pulmonary mast cells by bronchoalveolar allergen challenge: in vivo release of histamine and tryptase in atopic subjects with and without asthma
Am Rev Respir Dis
(1988)
AJ Wardlaw et al.
Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma—relationship to bronchial hyperreactivity
Am Rev Respir Dis
(1988)

CA Kelly et al.

Lymphocyte subsets in bronchoalveolar lavage fluid obtained from stable asthmatics and their correlation with bronchial responsiveness

Clin Exp Allergy

(1989)

M Tomoika et al.

Mast cells in bronchoalveolar lumen of patients with bronchial asthma

Am Rev Respir Dis

(1984)

KC Flint et al.

Bronchoalveolar mast cells in extrinsic asthma: a mechanism for the initiation of antigen-specific bronchoconstriction

Br Med J

(1985)

E Adelroth et al.

Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage

Am Rev Respir Dis

(1990)

LM Fabbri et al.

Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene disocyanate

Am Rev Respir Dis

(1987)

Cited by (601)

Clinical characteristics, cytokine profiles and plasma IgE in adults with asthma
2022, Molecular Immunology
Asthma is a disease with complicated network of inflammatory responses of cytokines and ImmunoglobulinE (IgE). The aim of this study was to explore the clinical characteristics, cytokine profile and plasma IgE in the Malaysian population. This is a cross-sectional study involving physician-diagnosed asthma patients (n = 287) recruited from the Chest Clinic, University of Malaya Medical Centre (UMMC). Blood (8 mL) was taken after consent was obtained. The peripheral blood leucocytes (PBL) were cultured in presence of a mitogen for 72 h to quantify cytokines [Interleukin-5(IL-5), Interleukin-9 (IL-9), Interleukin-12 Beta (IL-12ꞵ) and granulocyte-macrophage colony-stimulating factor (GM-CSF)] and plasma was used to quantify IgE levels with commercial ELISA kits. Results were compared against the same biomarkers in healthy subjects (n = 203). In addition, the amount of the biomarkers in the asthma patients were compared with their disease severity and clinical characteristics. Statistical tests in the SPSS software (Mann-Whitney U test and the Kruskal Wallis) were used to compare cytokine production and plasma IgE levels. The mean plasma IgE level was markedly higher (p < 0.0001) in asthmatics compared to controls. There were higher levels of IL-5, IL-9, IL-12ꞵ and GM-CSF (p < 0.0001) produced by cultured PBL from asthma patients compared to controls. However, our results did not expose a significant association between these cytokine levels and severity and clinical symptoms of asthma. However, there was a marked association between asthma severity and blood lymphocyte count [ꭓ²(2) = 6.745, p < 0.05]. These findings support the roles played by cytokines and IgE in the airway inflammation in asthma. The findings of this study provide new information about inflammatory cytokines in Malaysian asthma patients.
Borneol inhibits CD4 + T cells proliferation by down-regulating miR-26a and miR-142-3p to attenuate asthma
2021, International Immunopharmacology
Asthma is a chronic airway inflammatory disease caused by a variety of cytokines and signaling pathways closely related to immunoregulation. Corticosteroids are the most widely used drug in the asthma treatment. However, the use of corticosteroids could cause topical side effects. So, it’s important to find new drugs for asthma treatment. Our study aims to explore the pharmacological effect of borneol on asthma and its underlying mechanism.
We constructed the OVA-induced asthma model to investigate the effect of borneol on asthma in mice. HE and PAS staining was used to detect the effect of borneol on pathological change of mice with asthma. Inflammatory cytokines were measured by ELISA. qRT-PCR was used to explore the effect of borneol on microRNAs expression. Cell proliferation of CD4 + T cells was detected by CCK-8 assay and flow cytometry. Western blot was used to detect pten expression and Akt activation.
We found that borneol significantly alleviated asthma progression in mice. Borneol inhibited CD4 + T cells infiltration in vivo and proliferation in vitro by downregulating miR-26a and miR-142-3p. miR-26a and miR-142-3p promoted CD4 + T cells proliferation in vitro through targeting Pten. Overexpression of miR-26a and miR-142-3p abolished the effect of borneol in vivo.
In a word, these findings suggested that borneol attenuated asthma in mice by decreasing the CD4 + T cells infiltration. The molecular mechanism of borneol was dependent on the downregulation of miR-26a and miR-142-3p to upregulate the Pten expression.
An official JRS statement: The principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice
2021, Respiratory Investigation
Nitric oxide (NO) is produced in the body and has been shown to have diverse actions in the abundance of research that has been performed on it since the 1970s, leading to Furchgott, Murad, and Ignarro receiving the Nobel Prize in Physiology or Medicine in 1998. NO is produced by nitric oxide synthase (NOS). NOS is broadly distributed, being found in the nerves, blood vessels, airway epithelium, and inflammatory cells. In asthma, inflammatory cytokines induce NOS activity in the airway epithelium and inflammatory cells, producing large amounts of NO. Measurement of fractional exhaled nitric oxide (FeNO) is a simple, safe, and quantitative method of assessing airway inflammation. The FeNO measurement method has been standardized and, in recent years, this noninvasive test has been broadly used to support the diagnosis of asthma, monitor airway inflammation, and detect asthma overlap in chronic obstructive pulmonary disease (COPD) patients. Since the normal upper limit of FeNO for healthy Japanese adults is 37 ppb, values of 35 ppb or more are likely to be interpreted as a signature of inflammatory condition presenting features with asthma, and this value is used in clinical practice. Research is also underway for clinical application of these measurements in other respiratory diseases such as COPD and interstitial lung disease. Currently, there remains some confusion regarding the significance of these measurements and the interpretation of the results. This statement is designed to provide a simple explanation including the principles of FeNO measurements, the measurement methods, and the interpretation of the measurement results.
The synergistic or adjuvant effect of DINP combined with OVA as a possible mechanism to promote an immune response
2020, Food and Chemical Toxicology
Citation Excerpt :
AHR is a recognized feature of allergic asthma and is believed to be the result of airway mucosal inflammation, epithelial damage, and smooth muscle hypertrophy associated with goblet cell proliferation. Clinical studies have shown that the presence of activated airway inflammatory cells (including T cells, mast cells, monocytes, eosinophils and neutrophils) result in morphological changes in airway tissues and the occurrence and severity of AHR (Bradley et al., 1991; Wardlaw et al., 1988 and Wenzel et al., 1997). It is increasingly clear that T cells coordinate the inflammatory response that leads to AHR, by regulating the recruitment of effector cells and the release of specific cytokines.
Diisononyl phthalate (DINP) is commonly used as a plasticizer in industrial and consumer product applications. Several studies have suggested a possible link between exposure to DINP and the development of allergic asthma, and the synergistic effect of DINP combined with Ovalbumin (OVA) is a possible way to promote an immune response. These findings are still speculative, since there is insufficient evidence to assess the ability of DINP to influence “allergic asthma pathology”. This study was designed to determine any effects of OVA/DINP exposure on airway reactivity, particularly when combined with allergen exposure. Experiments to determine these effects were conducted after 15 days of combined exposure and a subsequent challenge with aerosolized ovalbumin for one week. Airway hyper-responsiveness (lung function), lung tissue pathology, cytokines and oxidative stress biomarkers were investigated. We showed that oral exposure to OVA/DINP could induce airway hyper-responsiveness (AHR), and aggravate airway wall remodeling, and that this deterioration was concomitant with increased immunoglobulin-E and Th2 cytokines secretion. The data also demonstrated that DINP could promote oxidative damage in the lung. In summary, this study showed that DINP has an adjuvant effect on allergic asthma affecting lung function, lung histopathology, immune molecules and causes oxidative damage.
Bronchoprovocation Testing in Asthma: An Update
2018, Immunology and Allergy Clinics of North America
Citation Excerpt :
Among nonatopics, elevated allergen-specific and polyclonal IL-10 production, TNFα, and IFNγ were associated with BHR, whereas BHR among atopic individuals was associated with eosinophilia, IL-5, and IgE.64 There are numerous epidemiologic and clinical trial studies that present associations, albeit modest, between BHR and features of atopy or other biomarkers of eosinophilic inflammation in the airway (from sputum, bronchoalveolar lavage, and exhaled substances).61,65–73 The associations with various measures of atopy can be variable.
Anti-allergy and anti-tussive activity of Clitoria ternatea L. in experimental animals
2018, Journal of Ethnopharmacology
Citation Excerpt :
These cytokines initiate infiltration of several types of cells including eosinophils, neutrophils, lymphocytes and phagocytes into the respiratory airways and thus initiates inflammation. It has also been postulated that eosinophil degranulation can damage epithelial cells, modulate the function of smooth muscles of the airways and at molecular level it increases the level of IgE in respiratory airways (Bradley et al., 1991; Kritas et al., 2014; Jatakanon et al., 1999; Gibson et al., 2001; Baines et al., 2010; Wilson et al., 2013; Miranda et al., 2004; Bittar et al., 2015). It has also been suggested that under allergic conditions, allergens induce the aggregation of the high-affinity IgE receptor which is expressed on mast cell surface (Chung et al., 2014; Carr et al., 2016).
Clitoria ternatea flower is traditionally used in the treatment of respiratory disorders including bronchitis and is one of the ingredients in different Ayurvedic preparations that are used in respiratory disorders. However, till date there is no scientific report on the anti-asthmatic activity of this flower.
Ethanolic extract of Clitoria ternatea flowers (ECT) was evaluated for its anti-allergy and anti-tussive potential in experimental animals. Additionally, the anti-inflammatory potential of ECT was carried out to draw a plausible mechanism of action of the drug.
In-vitro anti-asthmatic activity of ECT was evaluated in goat tracheal chain and isolated guinea pig ileum preparations. Acute and chronic anti-asthmatic activity of ECT (100, 200 and 400 mg/kg; p.o.) was estimated in histamine aerosol exposed guinea pigs and in OVA sensitized and challenged mice respectively. Anti-tussive activity of ECT (100, 200 and 400 mg/kg; p.o.) was evaluated against sulfur dioxide- and citric acid-induced cough in experimental animals. Moreover, the anti-inflammatory activity of ECT (100, 200 and 400 mg/kg; p.o.) was evaluated against carrageenan- and acetic acid-induced inflammation in rats.
ECT attenuated histamine-induced contraction in both goat tracheal chain and isolated guinea pig ileum preparations. ECT (400 mg/kg) attenuated histamine-induced dyspnoea and OVA-induced changes in differential cell count in broncheoalveolar fluid, levels of interleukins (IL-1beta and IL-6) and immunoglobulin (OVA-sensitive IgG1) in animals. ECT (400 mg/kg) further ameliorated sulfur dioxide- and citric acid-induced cough in experimental animals. Additionally, ECT (400 mg/kg) attenuated inflammation in carrageenan and acetic acid challenged rodents.
Standardized ECT could be considered as a potential therapeutic alternative in the management of allergy-induced asthma.

View all citing articles on Scopus

^☆: Supported by grants from the Chest, Heart, and Stroke Association, and the National Asthma Campaign, U. K.

^∗: From the Departments of Allergy and Clinical Immunology, National Heart & Lung Institute, London.

^∗∗: From the Departments of Lung Pathology, National Heart & Lung Institute, London.

^∗∗∗: From the Royal Brompton and National Heart Hospital, London.

^∗∗∗∗: From the Medical College of Virginia, Virginia Commonwealth University, Richmond, Va.

View full text

Original articleEosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness☆

Abstract

J Allergy Clin Immunol

Lancet

Lancet

Damage of the airway epithelium and bronchial reactivity in patients with asthma

Am Rev Respir Dis

Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity

Am Rev Respir Dis

Cellular events in the bronchi in mild asthma and after bronchial provocation

Am Rev Respir Dis

Identification of activated T-lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma

Am Rev Respir Dis

Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions

Am Rev Respir Dis

Activation of pulmonary mast cells by bronchoalveolar allergen challenge: in vivo release of histamine and tryptase in atopic subjects with and without asthma

Am Rev Respir Dis

Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma—relationship to bronchial hyperreactivity

Am Rev Respir Dis

Lymphocyte subsets in bronchoalveolar lavage fluid obtained from stable asthmatics and their correlation with bronchial responsiveness

Clin Exp Allergy

Mast cells in bronchoalveolar lumen of patients with bronchial asthma

Am Rev Respir Dis

Bronchoalveolar mast cells in extrinsic asthma: a mechanism for the initiation of antigen-specific bronchoconstriction

Br Med J

Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage

Am Rev Respir Dis

Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene disocyanate

Am Rev Respir Dis

Original article
Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness☆